To include your compound in the COVID-19 Resource Center, submit it here.

Celyad, Ono Pharmaceutical deal

Celyad granted Ono exclusive rights to develop and commercialize its allogeneic NKR2 T-cell

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE